We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal-bolus treatment with mealtime insulin aspart in Type 1 diabetes (BEGIN<sup>®</sup> Basal-Bolus Type 1): 2-year results of a randomized clinical trial
- Authors
Bode, B. W.; Buse, J. B.; Fisher, M.; Garg, S. K.; Marre, M.; Merker, L.; Renard, E.; Russell‐Jones, D. L.; Hansen, C. T.; Rana, A.; Heller, S. R.
- Abstract
Aims The goal of this study was to compare the long-term safety and efficacy of the basal insulin analogue, insulin degludec with insulin glargine (both with insulin aspart) in Type 1 diabetes, over a 2-year time period. Methods This open-label trial comprised a 1-year main trial and a 1-year extension. Patients were randomized to once-daily insulin degludec or insulin glargine and titrated to pre-breakfast plasma glucose values of 3.9-4.9 mmol/l. Results The rate of nocturnal confirmed hypoglycaemia was 25% lower with insulin degludec than with insulin glargine ( P = 0.02). Rates of confirmed hypoglycaemia, severe hypoglycaemia and adverse events, and reductions in glycated haemoglobin and fasting plasma glucose were similar between groups. Despite achieving similar glycaemic control, insulin degludec-treated patients used 12% less basal and 9% less total daily insulin than did insulin glargine-treated patients ( P < 0.01). Conclusions Long-term basal therapy using insulin degludec in Type 1 diabetes required lower doses and was associated with a 25% lower risk for nocturnal hypoglycaemia than insulin glargine.
- Subjects
INSULIN pharmacokinetics; INSULIN therapy; CLINICAL drug trials; CLINICAL trials; DIABETES; HYPOGLYCEMIA; INSULIN; METABOLIC regulation; SAFETY; DISEASE risk factors
- Publication
Diabetic Medicine, 2013, Vol 30, Issue 11, p1293
- ISSN
0742-3071
- Publication type
Article
- DOI
10.1111/dme.12243